about
Treatment options in recurrent ovarian cancer: latest evidence and clinical potential.Ovarian adenosarcoma simulating a simple cyst in a young patientEffect of lymphovascular space invasion on survival of stage I epithelial ovarian cancerOvarian Sertoli-Leydig cell tumor with heterologous elements of gastrointestinal type associated with elevated serum alpha-fetoprotein level: an unusual case and literature reviewWell-defined single polymer nanoparticles for the antibody-targeted delivery of chemotherapeutic agents.Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer.The Impact of Diabetes on Gynecologic Cancer: Current Status and Future Directions.A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian CarcinomasUpregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinomaUse of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer.The effectiveness of regional cooling for paclitaxel-induced peripheral neuropathyObserved-to-expected ratio for adherence to treatment guidelines as a quality of care indicator for ovarian cancer.Risk factors and a prediction model for lower limb lymphedema following lymphadenectomy in gynecologic cancer: a hospital-based retrospective cohort study.MicroRNA-20a contributes to cisplatin-resistance and migration of OVCAR3 ovarian cancer cell line.Novel ABCG2 Antagonists Reverse Topotecan-Mediated Chemotherapeutic Resistance in Ovarian Carcinoma Xenografts.Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer.Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer.The clinical utility of an elevated-risk multivariate index assay score in ovarian cancer patients.Diagnoses and Management of Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: Reactions to Taxanes and Monoclonal Antibodies.Hyperthermic Intraperitoneal Chemotherapy after Secondary Cytoreduction in Epithelial Ovarian Cancer: A Single-center Comparative Analysis.Preoperative hyponatremia in women with ovarian cancer: An additional cause for concern?Characteristics, treatment and outcomes of women with immature ovarian teratoma, 1998-2012.Right Place, Right Time: Preferences of Women with Ovarian Cancer for Delivery of CAM Education.The efficacy and safety of pegylated liposomal doxorubicin monotherapy and combination therapy with carboplatin in Korean patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer: a single-institution experience.PAX8 is a potential marker for the diagnosis of primary epithelial ovarian cancer.Diagnostic imaging using positron emission tomography for gynecological malignancy.Astragalus polysaccharides increase the sensitivity of SKOV3 cells to cisplatin.Management of Borderline Ovarian Tumors-Still a Gray Zone.miR-148a-3p suppresses epithelial ovarian cancer progression primarily by targeting c-Met.[PET-CT in head and neck cancer].Autophagy mediates epithelial cancer chemoresistance by reducing p62/SQSTM1 accumulation
P2860
Q27692699-1634581E-F05C-439C-A8DE-5A89FEB250CBQ33738035-B587663A-CB5E-4DC2-A320-47A83F4A6AFAQ34241202-6B1C1D5C-C47D-404A-A9DC-E71C72BF1969Q35388244-42ED2FE1-9740-463F-AEBD-79B26111C472Q35751371-7FAB3856-1DEF-491F-AB2D-CF230A5081C0Q36140826-E8EA3004-458C-4E17-ABEC-69521C47F8C3Q36494695-A4816152-9565-49A9-A42E-F8D5AE8F07B1Q36521889-469FD7DE-8DB4-422D-BD86-52EE3852890CQ36922664-C7D4324D-0CE7-41CE-A83C-EC84AFDF60E5Q37409836-B94C3696-2BEB-4F47-BCDA-D13D904A2481Q37417070-EF54391B-D113-40EB-ACC9-A16FF486D32AQ37486444-FA44B197-EDED-49CF-AF3B-35E32DBB9042Q38661875-1743BC47-4402-46A5-84A0-591D36F11967Q38695476-99CF5A04-811D-4C58-98BC-5741F0D83775Q38743568-F471FFCB-3F5C-479C-8BA7-11BAEA0DBF54Q38769834-F3DDEAB2-5F1E-4F0D-9C43-52F369FAC935Q38777716-EDBD3D13-F4EF-48B4-869E-0991C74652E6Q38800078-3F352730-C914-4284-B182-CBFF769BF551Q38859163-B0C553F3-E096-4EA9-B010-48B6183C053FQ40251231-EA0F1524-BF04-43D0-AC98-012DF46B000BQ40387712-12DBF742-3AA7-49F5-98A2-A3F32B8C1892Q40737174-EF245ADE-07D3-4435-9AEF-C00DB393682FQ41748028-B2F43A12-BA65-414A-93C6-7D3E6A2BFA8AQ42073473-9F11EC02-E428-4988-A122-77A65590F2CDQ47103850-0B1ED876-8ECD-45F7-937B-77B6E99397D1Q48105266-CD5DCA38-B030-468E-B572-802584E5F85DQ48364968-658B7544-C74F-4A05-ABDA-E1D22FDDF2C5Q50080187-4A84036E-EF3A-4336-A612-B9DE0F088A19Q52608483-59C81DE8-DCEE-45C1-B8D2-D530B763132DQ52944077-0763177E-2909-4B5E-922A-3D235BEBDC32Q57246602-9252C146-F861-4D3D-BFB6-AF0AE08A9EC2
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Ovarian cancer, version 2.2013.
@en
Ovarian cancer, version 2.2013.
@nl
type
label
Ovarian cancer, version 2.2013.
@en
Ovarian cancer, version 2.2013.
@nl
prefLabel
Ovarian cancer, version 2.2013.
@en
Ovarian cancer, version 2.2013.
@nl
P2093
P356
P1476
Ovarian cancer, version 2.2013.
@en
P2093
Ardeshir Hakam
Carolyn Johnston
David M Gershenson
David M O'Malley
Deborah K Armstrong
Heidi J Gray
Joseph T Santoso
Julian C Schink
Lainie Martin
Larry Copeland
P304
P356
10.6004/JNCCN.2013.0142
P577
2013-10-01T00:00:00Z